Alterations of MEN1 and E-cadherin/β-catenin complex in sporadic pulmonary carcinoids

SERENA VESCHI1, ROSSANO LATTANZIO1, GITANA MARIA ACETO1, MARIA CRISTINA CURIA2, SALVATORE MAGNASCO3, DOMENICO ANGELUCCI4, ALESSANDRO CAMA3, MAURO PIANTELLI1 and PASQUALE BATTISTA1

Departments of 1Experimental and Clinical Sciences, 2Medical, Oral and Biotechnological Sciences and 3Drug Sciences, University ‘G. d’Annunzio’-Chieti-Pescara; 4Division of Pathology, ‘SS. Annunziata’ Hospital, I-66013 Chieti, Italy

Received May 30, 2012; Accepted June 29, 2012

DOI: 10.3892/ijo.2012.1563

Abstract. Pulmonary carcinoids, distinct in typical and atypical, represent 2-5% of all primary lung tumors. The aim of this study was to investigate the molecular alterations correlated with the development of this form of neoplasms. A collection of 38 paraffin-embedded apparently sporadic carcinoids was investigated, through a combined study, for protein expression/localization of menin, p53, β-catenin and E-cadherin and for mutational analysis of the MEN1, TP53 and CTNNB1 genes. Menin was expressed in 71% of cases, with a prevalent cytoplasmic (c) localization, β-catenin was expressed in 68.4% of cases, of which 36.8% with a membranous (m) and 31.6% with a cytoplasmic localization. Membranous E-cadherin immunoreactivity was detected in 84.2% cases, nuclear p53 expression in 5.3% of cases. Positive correlation was found between c-menin and c-β-catenin expression (rho=0.439, P=0.008). In addition, m-β-catenin showed a positive correlation with both c-β-catenin and E-cadherin expression (rho=0.380, P=0.022 and rho=0.360, P=0.040, respectively). With regard to the E-cadherin/β-catenin complex, we found also a significant positive correlation between c-menin and β-disarrayed β-catenin expression (rho=0.481, P=0.007). MEN1 gene variants were characterized in 34% of cases. c-menin was more highly expressed in tumors with MEN1 variants, compared to tumors without MEN1 variants (P=0.023). Three nucleotide variants of TP53 were also detected. This study confirms the involvement of the MEN1 gene in the development of sporadic pulmonary carcinoids, demonstrates the accumulation of menin in the cytoplasm, and indicates that the disarrayed pattern of the complex significantly correlates with c-menin accumulation.

Introduction

Pulmonary carcinoids (PCs) account for ~2-5% of all primary lung tumors (1) and on the basis of the histopathological, biological and clinical features are distinct in typical and atypical carcinoids (TCs and ACs respectively) (2). This distinction is based on neuroendocrine morphology, number of mitoses, absence or presence of necrosis and size of primary tumor (3). Most PCs are confined to the main or lobar bronchi (4), however, 10-15% of cases present with regional lymph node metastases, thus they are classified as malignant, albeit low-grade, neoplasms (1). Distant metastases involving liver, bone, adrenal gland and brain occur in 15% of cases (5). The 5-year survival of TCs is 87-100%, whereas ACs have a more aggressive clinical course, with a 5-year survival of 37-71% (4).

PCs are rare and usually occur sporadically. Infrequently (5%) they arise in association with multiple endocrine neoplasia type 1 (MEN1), an autosomal-dominant familial tumor syndrome characterized by a high frequency of endocrine neoplasms (6). The MEN1 gene is also implicated in the pathogenesis of sporadic PCs, and mutations of this gene have been the first genetic alterations identified in these tumors (6). Somatic MEN1 mutations have been detected in 35% of bronchial carcinoid tumors (7). Overall, inactivation of the MEN1 gene by mutation is detectable in ~47% of sporadic TCs and in ~70% of sporadic ACs (8). Recently, somatic inactivating mutations in MEN1 have been also reported in 44% of pancreatic neuroendocrine tumors (9,10). Menin, the protein encoded by the MEN1 gene, is a component of histone methyltransferase complexes (11-13) and is ubiquitously expressed. It is predominantly a nuclear protein in non-dividing cells, but in dividing cells it is found mainly in the cytoplasm (7). Menin regulates gene transcription, cell proliferation, apoptosis and genomic stability. One of the proteins interacting with menin is β-catenin, an E-cadherin signaling component, that acts as a transcription factor and whose dysregulation has been associated with the development and progression of many solid tumors, including several types of endocrine tumors (14,15). The E-cadherin/β-catenin complex localizes at the cell membrane in essentially all normal and hyperplastic neuroendocrine cells of the lower respiratory tract, giving rise to a membrane-linear immunostaining pattern. The expression of the E-cadherin/β-catenin complex appears...
conserved in pulmonary neuroendocrine tumors. However, the subcellular compartmentalization of E-cadherin and β-catenin is profoundly heterogeneous in diverse tumor types, and reflects in a differential distribution of the membrane-linear/disarrayed immunostaining pattern ratio (13). Only a minority of lung neuroendocrine tumors show a nuclear translocation of β-catenin, most cases showing a membranous colocalization with E-cadherin. The β-catenin nuclear accumulation appears to be an exclusive feature of a subset of high-grade neuroendocrine tumors (14). Consistently, abnormal cytoplasmic and/ or nuclear localization of the E-cadherin/β-catenin complex are independent predictors of lymph node metastasis in ACs (14,15). Finally, LOH and point mutations of the TP53 locus on chromosome 17p13 have also been detected in 10% of TCs and in 45% of ACs, and were proposed to increase with the severity of the tumor type (16).

However, a comprehensive scenario of the molecular alterations associated with PCs and of their interactions is still missing. Hence, we investigated 38 sporadic PCs for protein expression/localization (nuclear, cytoplasmic and membranous) of menin, p53, E-cadherin and β-catenin combined with mutational analysis of MEN1, TP53, CTNNB1 genes. Our findings show correlations of specific alterations patterns in different sub-sets, thus suggesting different molecular mechanisms in tumor sub-groups. This may reflect in differential molecular taxonomy of PCs.

Materials and methods

Tissue samples. Archived formalin-fixed paraffin-embedded (FFPE) blocks of 38 apparently sporadic PCs consecutively diagnosed between 2001-2008 at the Institute of Pathology, ‘S.S.Annunziata’ Hospital, Chieti, Italy were retrieved. All tumors were reviewed for diagnosis. Cases were classified as TC (30 cases) or AC (8 cases) carcinoid tumors (WHO classification) (2). For each case both tumor and normal tissues were available. The study was reviewed and approved by the ethics committee of the ‘S.S. Annunziata’ Hospital.

Tissue microarray (TMA) construction and IHC. TMA was constructed by extracting 2-mm diameter cores of histologically confirmed neoplastic area and re-embedding the cores into gridded paraffin blocks, using a precision instrument (Beecher Instruments, Sun Prairie, WI). TMA sections were stained using the anti-Menin polyclonal rabbit antibody (1:350 dilution, 30 min, Bethyl Laboratories Inc., Montgomery, TX). For β-catenin, in order to validate the results of the immunohistochemistry analysis, we used two commercially available mouse monoclonal antibodies raised against the C-terminal domain of β-catenin, clone 17C2 (1:100 dilution, 60 min, Novocasta Laboratories Ltd., Newcastle, UK) and 14/β-catenin (1:150 dilution, 60 min, BD Transduction Laboratories, San Jose, CA). The anti-E-cadherin (1:50 dilution, 30 min, HEC-1, Zymed Laboratories Inc., San Francisco, CA) and the anti-p53 (1:50 dilution, 30 min, DO7, Novocasta) mouse monoclonal antibodies were also used. Antigen retrieval was performed by microwave treatment at 750 W for 10 min in 10 mM sodium citrate buffer pH 6.0 (S2031, Dako, Glostrup, Denmark), except for sections stained with the anti-p53 antibody that were treated in thermostatic bath at 96°C for 40 min in sodium citrate buffer (Dako) The anti-mouse and the anti-rabbit EnVision kits (Dako) were used for signal amplification, as appropriate. In control sections the specific primary antibody was omitted or replaced with non-immune serum or isotype-matched immunoglobulins.

Immunohistochemical results were evaluated by two pathologists (M. Piantelli and R. Lattanzio) by consensus without knowledge of the clinicopathologic information. Menin and p53 status were considered positive when ≥1% of the tumor cells were stained. The immunostaining pattern of tumor cells for β-catenin and E-cadherin was defined as arrayed or disarrayed according to the immunohistochemical criteria proposed by Pelosi et al (14). Arrayed staining was defined as a membrane-associated, linear pattern of immuneactivity for β-catenin and E-cadherin, which decorated entire the cell membrane. Disarrayed staining was defined as a membrane staining observed along with variable cytoplasmic accumulation or if a prevalent cytoplasmic staining with only minimal or absent membrane labeling.

DNA extraction. Representative areas of tumor and normal tissues were identified within hematoxylin-counterstained deparaffinized sections and separated by manual microdissection into 1.5 ml polypropylene vials. For DNA extraction we cut FFPE unsectioned core samples from the interior of the paraffin blocks selecting tumor and surrounding normal lung tissue areas. Tumor and non-tumor DNAs were extracted using the RecoverAll™ Total Nucleic Acid Isolation kit according to the manufacturer's instructions (Applied Biosystems, Forster City, CA). Purified DNA was easily amplifiable and suitable for denaturing high performance liquid chromatography (DHPLC) analysis.

Mutational analysis. DHPLC and direct sequence techniques were used to analyze the entire coding sequence of MEN1 gene, exons 5-8 of TP53 gene and exon 3 of the CTNNB1 gene for somatic mutations. DHPLC was performed using the Wave® Nucleic Acid Fragment Analysis system (Transgenomic Inc., San Jose, CA) and sequencing analysis using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). Each sample was analysed for somatic nucleotide variants, by sequence comparison of tumor and non-tumor DNA. We analyzed PCR amplicons of DNA extracted from FFPE tissues by DHPLC. Tumor DNAs were analyzed for the entire MEN1 coding sequence, including intron-exon boundaries, using 13 PCR primer sets for exons 1-10, as previously described (17). We designed also a set of primers to amplify the last part of exon 10 (forward: AACTCGAGCGCCATCAAGC; reverse: GG GCC TCA GAG TTT GGG GAG ACT A). For exons 5-8 of the TP53 gene nested PCR amplifications were performed using primers previously described (18,19). Direct PCR for exon 3 of the CTNNB1 gene was carried out using the forward primer designed in our laboratory (forward: TGATT TTGAT CGG AGTTT GGC AC) and the reverse primer previously reported (15). Tolerance prediction of amino acid changes was tested by SIFT version 2 (available at http://blocks.fhcrc.org/sift/SIFT.html) (20). The fruitly software (www.fruitly.org) was used to assess in silico predicted effects on splicing of intron nucleotide variants.

Statistical data analysis. Comparisons between molecular markers were done by the Spearman's Rho correlation. The
independent samples t-test was used to compare the expression of molecular markers in PCs according to MEN1 gene status. The SPSS program (version 15.0, SPSS Inc., Chicago, IL, USA) was used for statistical analysis. All cited P-values are two-sided; P<0.05 was considered as statistically significant.

Results

Immunohistochemistry. The results of the IHC analysis for menin, β-catenin, E-cadherin and p53 expression performed on 38 PCs are reported in Table I and examples of specific immunohistochemical stainings are shown in Fig. 1. There were in total 27 menin positive tumors out of 38 (71.0%), of these, 26 out of 38 (68.4%) cases expressed menin in the cytoplasm of tumor cells (c-menin) with a mean value of positive tumor cells of 44.7±6.1 (mean ± SE) and 3 out of 38 (7.9%) tumors, two of which were also c-menin positive.

Table I. Expression of immunohistochemical markers in PCs.

| Marker        | Positive cases | Positive tumor cells<sup>a</sup> |
|---------------|----------------|----------------------------------|
| c-Menin       | 26 (68.4)      | 44.7±6.1                         |
| n-Menin       | 3 (7.9)        | 2.3±2.1                          |
| m-β-catenin   | 14 (36.8)      | 8.0±3.1                          |
| c-β-catenin   | 12 (31.6)      | 16.7±5.0                         |
| n-β-catenin   | 0              |                                  |
| E-cadherin    | 32 (84.2)      | 58.6±6.7                         |
| n-p53         | 2 (5.3)        | 2.1±1.9                          |

<sup>a</sup>Values given as mean (%) ± SE; c, cytoplasmic; n, nuclear; m, membranous.
showed specific nuclear immunoreactivity for menin (n-menin) (2.3±2.1).
β-catenin-positive cases were 26 out 38 (68.4%). No differences in the β-catenin immunostaining were observed using the two different monoclonal antibodies. Membranous β-catenin (m-β-catenin) expression was observed in 14 out of 38 (36.8%) cases, whereas cytoplasmic β-catenin (c-β-catenin) was detected in 12 out of 38 (31.6%) cases. Coexpression of m-

Table II. Spearman’s correlations between markers in PCs.
A.

|                 | c-Menin | n-Menin | m-β-catenin | c-β-catenin | E-cadherin |
|-----------------|---------|---------|-------------|-------------|------------|
| c-Menin         |         |         |             |             |            |
| Rho⁴            | 1       | -0.093  | 0.196       | 0.439       | -0.014     |
| P               | 0.597   | 0.259   | 0.008       | 0.936       |            |
| n-Menin         |         |         |             |             |            |
| Rho             | -0.093  | 1       | -0.077      | 0.007       | 0.004      |
| P               | 0.597   | 0.661   | 0.960       | 0.983       |            |
| m-β-catenin     |         |         |             |             |            |
| Rho             | 0.196   | -0.077  | 1           | 0.380       | 0.360      |
| P               | 0.259   | 0.661   | 0.960       | 0.983       |            |
| c-β-catenin     |         |         |             |             |            |
| Rho             | 0.439   | 0.007   | 0.380       | 1           | 0.172      |
| P               | 0.008   | 0.960   | 0.022       | 0.340       |            |
| E-cadherin      |         |         |             |             |            |
| Rho             | -0.014  | 0.004   | 0.360       | 0.172       | 1          |
| P               | 0.936   | 0.983   | 0.040       | 0.340       |            |

B.

|                 | c-Menin | β-catenin (arrayed) | β-catenin (disarrayed) | E-cadherin (arrayed) | E-cadherin (disarrayed) |
|-----------------|---------|---------------------|------------------------|----------------------|-------------------------|
| c-Menin         |         |                     |                        |                      |                         |
| Rho⁴            | 1       | -0.479              | 0.481                  | 0.213                | 0.054                   |
| P               | 0.230   | 0.007               | 0.318                  | 0.856                |                         |
| β-catenin       |         |                     |                        |                      |                         |
| arrayed         |         |                     |                        |                      |                         |
| Rho             | -0.479  | 1                   | -0.049                 | -0.127               |                         |
| P               | 0.230   | 0.765               |                        |                      |                         |
| disarrayed      |         |                     |                        |                      |                         |
| Rho             | 0.481   | 1                   | 0.081                  | 0.029                |                         |
| P               | 0.007   | 0.765               | 0.765                  | 0.922                |                         |
| E-cadherin      |         |                     |                        |                      |                         |
| arrayed         |         |                     |                        |                      |                         |
| Rho             | 0.213   | -0.127              | 0.081                  | 1                    |                         |
| P               | 0.318   | 0.765               | 0.765                  | 0.922                |                         |
| disarrayed      |         |                     |                        |                      |                         |
| Rho             | 0.054   | 0.029               | 1                      |                      |                         |
| P               | 0.856   | 0.922               |                        |                      |                         |

⁴Rho, Spearman’s coefficient correlation; significant correlations (P<0.05) in bold.
Table III. Data on allelic variants of *MEN1* gene and correlations with the percentage of positive tumor cells expressing menin, p53, β-catenin and E-cadherin immunostaining.

| Case no. | *MEN1* variant | Exon | Effect | c-menin | n-menin | n-p53 | m-β-catenin | c-β-catenin | E-cadherin |
|----------|----------------|------|--------|---------|---------|-------|-------------|-------------|------------|
| TC       |                |      |        |         |         |       |             |             |            |
| 2        | c.1254T        | 9    | p.N418N| 72      | 0       | 0     | 2           | 54          | 12         |
| 9        | c.446-5C>T     | IVS2 | No effect on splicing | 100 | 0 | 0 | 6 | 63 | 100 |
| 11       | c.1254C>T      | 9    | p.N418N| 93      | 0       | 0     | 88          | 92          | 74         |
| 12       | c.446-5C>T     | IVS2 | No effect on splicing | 40  | 0 | 0 | 0 | 0 | 26 |
| 15       | c.435C>T       | 2    | p.S145S| 98      | 0       | 0     | 4           | 82          | 78         |
| 16       | c.1254C>T      | 9    | p.N418N| 100     | 0       | 0     | 0           | 31          | 97         |
| 23       | c.427delC      | 2    | p.L143fsX184| 81 | 0 | 0 | 3 | 0 | 95 |
| 24       | c.296A         | 2    | p.G99S | 0       | 0       | 0     | 0           | 0           | 41         |
| 37       | c.1254C>T      | 9    | p.N418N| 0       | 0       | 0     | 7           | 8           | 0          |
| AC       |                |      |        |         |         |       |             |             |            |
| 27       | c.646G>A       | 3    | p.A216T| 42      | 4       | 68    | 0           | 0           | 100        |
| 28       | c.1254T        | 9    | p.N418N| 49      | 0       | 0     | 42          | 0           | 98         |
| 29       | c.147T>G       | 2    | p.A49A | 82      | 0       | 0     | 1           | 0           | 3          |
| 33       | c.266T>G       | 9    | p.L89R | 55      | 0       | 0     | 45          | 53          | 96         |
|          | c.1254T        | 2    | p.N418N|         |         |       |             |             |            |

c-, cytoplasmic; m-, membrane; n-, nuclear.
and c-β-catenin was detected in 6 cases. The mean values of β-catenin-positive tumor cells were 8.0±3.1 for m-β-catenin and 16.7±5.0 for c-β-catenin. β-catenin was not expressed in the nucleus of tumor cells. E-cadherin immunoreactivity was observed exclusively in cell membrane and detected in 32 out of 38 (84.2%) cases with a mean ± SE of positive tumor cells of 1226. The nuclear expression of p53 was observed exclusively in the nucleus of tumor cells. E-cadherin immunoreactivity was found in 2 out of 38 (5.3%) cases, with a mean ± SE of tumor positive cells of 2.1±1.9.

Correlations between markers, were analyzed using the Spearman's coefficient correlation test. A significant positive correlation was found between c-menin and c-β-catenin expression (rho=0.439, P=0.008) (Table IIA). Furthermore, m-β-catenin showed a positive correlation with both c-β-catenin and E-cadherin expression (rho=0.380, P=0.022 and rho=0.360, P=0.040, respectively). With regard to the protein status of the E-cadherin/β-catenin complex, following the criteria suggested by Pelosi et al (14) we found a significant positive correlation between c-menin and β-catenin disarrayed expression (rho=0.481, P=0.007) (Table IIB).

Table IV. Correlations between Menin expression and MEN1 gene status.

| Positive tumor cells | Mean ± SE\(^a\) | P-value\(^b\) |
|----------------------|------------------|--------------|
| c-Menin              |                  |              |
| PCs with MEN1 mutations (n=13) | 62.5±9.7 | 0.023 |
| PCs without MEN1 mutations (n=25) | 34.2±7.1 |           |
| n-Menin              |                  |              |
| PCs with MEN1 mutations (n=13) | 0.3±0.3 | 0.485 |
| PCs without MEN1 mutations (n=25) | 3.4±3.2 |           |

\(^a\) Percent of positive tumor cells ± standard error. \(^b\) Independent samples t-test.


debut. C- and n-menin are co-expressed in 1 out of 13 MEN1 mutated cases, while c- and n-menin and n-p53 were co-expressed in only 1 case. Correlating the menin expression levels with the presence or absence of MEN1 nucleotide variants, we found that c-menin was significantly more expressed in tumors with MEN1 variants compared to tumors without MEN1 variants (P=0.023), whereas n-menin does not show a significant correlation when compared with PCs with and without MEN1 variants (Table IV). No differences were found comparing m- and c-β-catenin, m-E-cadherin and n-p53 expression levels with and without MEN1 variants (Table V). The expression of TP53, MEN1 and E-CADHERIN/β-CATENIN are not predicted to affect splicing. In Table V the expression of TP53, MEN1 and E-CADHERIN/β-CATENIN are not predicted to affect splicing.

Table V. Data on nucleotide variants of TP53, predicted effect on p53 protein and immunohistochemical expression.

| Case no. | Histotype | TP53 variant | Exon | Effect | Status (Reference) | SIFT | AGVGD | IHC |
|---------|-----------|--------------|------|--------|-------------------|------|-------|-----|
| 21      | TC        | c.387C>T     | 5    | p.A129A| IARC TP53 database | Silent | Silent | 0   |
| 27      | AC        | c.763T       | 7    | p.1255F| IARC TP53 database | Deleterious | Deleterious | 68<sup>a</sup> |
| 37      | TC        | c.639A>G     | 6    | p.R213R| IARC TP53 database | Silent | Silent | NA  |

<sup>a</sup>Percent of nuclear p53 immunostained cells.
Discussion

In this study we analyzed a series of 38 sporadic PCs for somatic mutations and for protein expression of genes that appear to be implicated in the development and progression of the disease. Combined genetic and IHC findings were used to identify relevant PC sub-groups and to help defining a combined role of genes potentially involved in the pathogenesis of PCs. This was done by evaluating the IHC expression of menin, p53, β-catenin and E-cadherin at subcellular level and by correlating the expression of these markers with the mutational spectra of the MEN1, TP53 and CTNNB1 genes in both TC and AC tumors.

A significant fraction of tumor samples (34%) harbored MEN1 gene variants. Most samples showed a cytoplasmic, rather than nuclear, localization of menin. Cytoplasmic localization of menin was observed in tumors with and without MEN1 variants. Only two cases with nuclear menin immunostaining did not display variants of the MEN1 gene.

Notably, tumors carrying MEN1 variants showed significantly higher cytoplasmic expression of the menin, when compared with samples negative for MEN1 variants. The cytoplasmic localization of menin was detected both in TCs and ACs, the highest fraction being observed in ACs (data not shown), i.e., in cases with higher rate of mitosis. Thus, our data on PC are in agreement with previous observations in pancreatic endocrine tumors in which a strong association between MEN1 variants and cytoplasmic localization of menin were observed (10). This is consistent with a role of this oncosuppressor gene in the pathogenesis of sporadic PCs. The analysis of the E-cadherin/β-catenin complex evidenced a significant correlation in the membranous and/or cytoplasmic expression of these two proteins. It is known that the complex plays a crucial role in cell-cell adhesion, and dysregulation of the E-cadherin/β-catenin-dependent adhesion complex has been associated with the development and progression of many solid tumors, including several types of endocrine tumors (14). Thus, we investigated a possible dysregulation of the complex in PCs. We observed β-catenin expression in the majority of tumor cases. However, in a fraction of PCs β-catenin tended to accumulate in the cytoplasm. Notably, we found also a significant direct relationship of c-β-catenin expression with c-menin expression and, following the immunohistochemical criteria suggested by Pelosi et al (13) who defined the immunostaining pattern of tumor cells for β-catenin and E-cadherin as arrayed or disarrayed, we searched for possible correlations between these patterns of immunostaining with the other markers analyzed. Intriguingly, we found a significant positive correspondence between the disarrayed expression of β-catenin with the c-menin expression. Consistent with the absence of nuclear β-catenin expression, we did not find mutations of the CTNNB1 gene (15), further indicating a role of this gene in PC pathogenesis, but not as a driver mutation. It is known that menin regulates gene transcription, cell proliferation, apoptosis and genomic stability and one of the proteins interacting with menin is β-catenin.

Single or multiple MEN1 sequence variants, consisting in frameshift, missense and silent variants were characterized in 13 out of 38 cases, with a prevalence in ACs compared to TCs. Three of the 4 missense variants characterized in our study were not reported up to now in association with PCs. The p.TS41A missense variant is a pathogenetic variant affecting the role of menin in the apoptosis control (22). The missense mutation p.L89R and the polymorphism p.S1455 were previously identified as somatic variants also in glucagonoma and parathyroid tumors. The p.L89R detected in case no. 33 was not tolerant using the SIFT Version 2 program and could interfere with menin protein structure and function. Cytoplasmic expression of menin and presence of nucleotide variants of the MEN1 gene may be indicative of a significant correlation, since cases with MEN1 nucleotide variants are characterized by a higher number of positive tumor cells expressing menin in the cytoplasmic compartment. It is noteworthy that high cytoplasmic expression of menin has been also detected in most of the cases bearing only the c.1254T polymorphism, suggesting a hypothetical possibility of this silent variant and c-menin accumulation in tumor cells. Thus, our data support the hypothesis that MEN1 gene variants affect the subcellular localization of the protein causing its accumulation in the cytoplasm. For cases without MEN1 variants and cytoplasmic menin expression, it may be possible that other genes, partners of MEN1, are responsible for the impairment of menin function in PCs. The results are in agreement with other studies on sporadic lung carcinoids (6).

Somatic mutation analysis of exons 5-8 of the TP53 gene, which encode the DNA-binding region where cancer-associated mutations most frequently occur (23-25), indicates that genetic alterations of this gene may be implicated in the development of a limited fraction of PCs. In this contest, it is relevant to note that the nucleotide variant c.763T at codon 255, detected in an APC with high immunohistochemical expression of p53, is reported to be deleterious in both the SIFT version 2 and AGVGD programs, where the tolerance of amino acid changes was tested. Thus, our results indicate that TP53, rather than playing a broad role in PCs (16,26), may operate in specific PC sub-groups, possibly by interacting with menin. Additional studies are required to test this model.

In conclusion, the present study confirmed the implication of MEN1 gene in the development of sporadic PC. Furthermore, the mutational study of MEN1 gene, associated with the IHC analysis of menin indicated that tumors displaying MEN1 nucleotide variant were characterized by a higher accumulation of menin in the cytoplasm and, for our knowledge, this strong association between MEN1 variants and cytoplasmic localization of menin has not been previously reported in sporadic pulmonary carcinoids, thus representing an interesting finding for this type of tumor.

In addition, this study also indicated that the subcellular compartmentalization of the E-cadherin/β-catenin complex was altered in PCs and the disarrayed pattern of the complex significantly correlated with c-menin accumulation, thus suggesting a possible cooperative role of menin and E-cadherin/β-catenin in the development and/or progression of this endocrine-related tumor.

References

1. Bini A, Brandolini J, Cassanelii N, Davoli F, Dolci G, Sellitri F and Stella F: Typical and atypical pulmonary carcinoids: our institutional experience. Interact Cardiovasc Thorac Surg 7: 415-418, 2008.
2. Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC: WHO Classification of Tumors: Pathology and Genetics of Tumours of the Lung, Pleura,Thymus and Heart. IARC Press, Lyon, 2004.
3. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA and Koss MN: Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22: 934-944, 1998.

4. Hage R, de la Rivière AB, Seldenrijk CA and van den Bosch JM: Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol 10: 697-704, 2003.

5. Jeung MY, Gasser B, Gangi A, et al: Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings. Radiographics 22: 351-365, 2002.

6. Debelenko LV, Brambilla E, Agarwal SK, et al: Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 6: 2285-2290, 1997.

7. Lemos MC and Thakker RV: Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 10: 437-450, 2003.

8. Catalano T, Curia MC, Aceto G, et al: Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. Oncol Rep 14: 625-631, 2005.

9. Kim H, Lee JE, Cho EJ, Liu JO and Youn HD: Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 63: 6136-6139, 2003.

10. Hughes CM, Rozenblatt-Rosen O, Milne TA, et al: Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 13: 587-597, 2004.

11. Yokoyama A, Wang Z, Wysocka J, et al: Leukemia protocadherin protein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 24: 5639-5649, 2004.

12. Pelosi G, Scarpa A, Pupp A, et al: Alteration of the E-cadherin/β-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Cancer 103: 1154-1164, 2005.

13. Clavel CE, Nollet F, Berx G, et al: Expression of the E-cadherin/β-catenin complex in lung neuroendocrine tumours. J Pathol 194: 20-26, 2001.

14. Leotilel PD, Jach A, Holtgreve-Grez H and Thakker RV: Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 10: 437-450, 2003.

15. Zhuang Z, Vortmeyer AO, Pack S, et al: Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 57: 4682-4686, 1997.

16. Catalano T, Curia MC, Aceto G, et al: Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. Oncol Rep 14: 625-631, 2005.

17. Mahdvavini M, Bishelsari F, Vergerin F, et al: P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol 216: 543-550, 2008.

18. Ng PC and Henikoff S: Accounting for human polymorphisms predicted to affect protein function. Genome Res 2: 436-446, 2002.